The global t-cell lymphoma market size was valued at USD 1,717.59 million in 2021. It is expected to reach USD 3,648.08 million by 2030, growing at a CAGR of 8.73% during the forecast period (2022–2030).
The blood cancer known as T-cell lymphoma develops from the body's immune system's T-cell lymphocytes, which grow and multiply uncontrollably. Peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma are the two main subtypes of T-cell lymphoma. In most cases, the cause of T-cell lymphomas is unknown. However, certain risk factors for developing T-cell lymphoma include viral infections like the Epstein-Barr virus or medical conditions like coeliac disease. A tissue biopsy, blood cell counts, PET (positron emission tomography), CT (computed tomography), MRI (magnetic resonance imaging), and other tests can be used to diagnose T-cell lymphoma. T-cell lymphoma can be treated in several ways, including chemotherapy, radiotherapy, immunotherapy, antiviral therapy, stem cell transplantation, and other methods.
One of the most prevalent blood cancers worldwide is lymphoma. It occurs when the immune system's white blood cells, known as lymphocytes, grow and multiply uncontrollably in the human body. Tumors are masses of cancerous lymphocytes that can develop in the lymph node, spleen, bone marrow, blood, or other organs. B-lymphocytes and T-lymphocytes are the two primary lymphocytes in the body that can develop into lymphomas (T- cells). Age raises the risk of non-Hodgkin lymphoma. A few typical non-Hodgkin lymphoma symptoms include enlarged lymph nodes, weight loss, fatigue, chest pain, and bleeding or easy bruising. Additionally, the incidence of lymphoma has grown globally over time. The demand for t-cell lymphoma therapies is anticipated to rise in response to the rising lymphoma cases, including non-Hodgkin lymphoma, across the regions, which is anticipated to propel the market's expansion.
Lymphocytes, a component of the body's immune system, are the cells from which lymphomas develop. Lymphocytes can grow and divide more due to an overactive immune system in autoimmune disorders, which raises the likelihood that lymphoma cells will develop. Strong risk factors for Hodgkin and non-Hodgkin lymphoma includes autoimmune diseases. According to the Lupus Foundation of America, 2020, 1.5 million Americans and at least five million others worldwide have some form of lupus. Ninety percent (90%) of lupus patients are female. Lupus typically strikes people between the ages of 15 and 44. The most prevalent form of lupus, systemic lupus erythematosus (SLE), increases the risk of lymphoma; as a result, the growth of the t-cell lymphoma market will be positively impacted by the rising prevalence of lupus. Thus, the prevalence of autoimmune diseases around the world raises the risk of lymphoma, boosting the market's overall growth.
Patients worldwide struggle significantly with the high cost of cancer treatments and medications. In a 2019 survey, the Mesothelioma Center at Asbestos.com found that 63% of cancer patients and their families experienced financial difficulties after receiving a cancer diagnosis and undergoing treatment. The increase in cancer drug costs over the previous two decades concerns the entire world's population. Cancer patients frequently face unaffordable treatment scenarios, particularly in low- and middle-income countries, due to the high costs involved, which often result in avoidable deaths.
The price of cancer treatments is influenced by several factors, including Many countries' universal insurance programs are poorly run, which prevents the adoption of better treatment options. Many cost-sharing or out-of-requirement issues affect patients with health insurance, ultimately driving up the treatment cost. These cost-sharing elements come with a significant premium payment. Some plans have separate deductibles for medical services, prescription medications, and out-of-network services, as well as for balance billing, out-of-pocket maximums, and unanticipated costs associated with treatments that are not covered by health insurance.
Due to the increasing number of non-Hodgkin lymphoma cancer cases worldwide and the extensive research being done by the key players, the t-cell lymphoma market is anticipated to experience strong growth and sizable market size. Novel therapies are essential for the development of clinical t-cell lymphoma cancer management in the future. The development of several new drugs with promising efficacy profiles has also been facilitated by advances in our understanding of the pathogeneses of cutaneous T cell lymphoma (CTCL). Additionally, photopheresis is currently advised to treat skin conditions like mycosis fungoides or Sezary syndrome connected to cutaneous t-cell lymphomas (CTCL). The Food and Drug Administration (FDA) has approved extracorporeal photopheresis (ECP) as the first therapy for treating cutaneous t-cell lymphoma. Therefore, health professionals must develop preventive and therapeutic strategies against t-cell lymphoma, which is anticipated to drive the t-cell lymphoma market significantly over the forecast period.
The global t-cell lymphoma market is segmented by type of lymphoma and type of therapy.
Based on the type of lymphoma, the global t-cell lymphoma market is bifurcated into peripheral t-cell lymphoma and t-cell lymphoblastic lymphoma.
The peripheral t-cell lymphoma segment is the highest contributor to the market and is expected to grow at a CAGR of 8.78% during the forecast period. Various aggressive lymphomas known collectively as peripheral t-cell lymphomas (PTCL) arise from the body's mature T- and natural killer (NK) cells. Nodal, extranodal, and leukemic PTCLs are divided into three categories by the World Health Organization (WHO), identifying subtypes of PTCLs within each category. It is crucial to receive a proper diagnosis and understand your specific PTCL subtype. The Leukemia and Lymphoma Society reports that PTCLs are highly uncommon in the US. Perhaps due to exposure to specific viruses like the Epstein-Barr virus (EBV) and human T-cell leukemia virus-1, they are more prevalent in Asia, Africa, and the Caribbean (HTLV-1).
A non-Hodgkin lymphoma subtype called T-cell lymphoblastic lymphoma most frequently affects children and adolescents. It is also known as acute lymphoblastic leukemia, depending on how much of the bone marrow is involved in the disease's manifestation. The American Cancer Society estimates that t-cell lymphoblastic lymphoma accounted for 1% of all lymphomas in 2018. Therefore, even though the condition is uncommon, developing better therapeutics and diagnostics is crucial. The t-cell acute lymphoblastic leukemia was found to be more common in boys. Still, the mortality rate was higher in girls, according to the "Childhood T-cell Acute Lymphoblastic Leukemia in a Single Latin American Center: Impact of Improved Treatment Scheme and Support Therapy on Survival," published in 2020. As a result, there is a growing need for better medical care to treat this disease, fueling market expansion.
Based on the type of therapy, the global t-cell lymphoma market is bifurcated into radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation.
The chemotherapy segment owns the highest market share and is expected to grow at a CAGR of 8.94% during the forecast period. Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy work by removing, killing or damaging the cancer cells in a particular area, but chemotherapy works throughout the whole body. This means that chemotherapy can destroy and damage cancer cells that have spread to other body parts away from the original tumor. Chemotherapy is used with surgery or radiation therapy, or both. In some cases, it is combined with other drugs, such as hormone therapy, targeted therapy, or immunotherapy. For example, chemo may be used to shrink a tumor before surgery or radiation therapy. Chemo used in this way is called neoadjuvant therapy or after surgery or radiation therapy to help kill any remaining cancer cells in the body. Chemo used in this way is called adjuvant therapy.
Cancer immunotherapy aids in the immune system's fight against the disease. Immunotherapies come in a variety of forms and are used to treat cancer. Checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, and cytokines are a few immunotherapies. It is a successful treatment for cutaneous t-cell lymphoma. In various t-cell lymphoma patients, CD30 CAR T cells offer the chance to quickly produce tumor-specific T cells, reducing side effects and enhancing antitumor activity.
By region, the global t-cell lymphoma market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
North America is the most significant shareholder in the global t-cell lymphoma market and is expected to grow at a CAGR of 8.66% during the forecast period. The pharmaceutical sector is one of the industries with the highest research expenditures in the US. The industry has a significant stake in using cutting-edge techniques to improve pipeline development and support advancements in patient care. In addition, the American Society of Clinical Oncology (2018) estimated that 10% of Americans with lymphoma had t-cell lymphoma. As a result, it is anticipated that the incidence of t-cell lymphoma in the United States will rise along with the incidence of lymphoma. Due to the region's rising t-cell lymphoma prevalence, numerous new treatments have been authorized. For example, the US Food and Drug Administration (FDA) increased the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral t-cell lymphoma in 2018. (PTCL). This was the first PTCL treatment regimen to receive FDA approval.
Europe is expected to grow at a CAGR of 8.82%, generating USD 982.77 million during the forecast period. One of the largest concentrations of pharmaceutical and healthcare organizations in Europe is Germany. The nation has a top-notch research infrastructure and internationally renowned scientists, which have helped it solidify its position as a global center for healthcare technology and boost the amount of research and advancements for treating novel and rare disorders. Germany spends about 6.2 billion euros annually on just R&D, or 15 million euros per day, according to the VFA (Verband Forschender Arzneimittelhersteller, German Association of Research-Based Pharmaceutical Companies). The market for t-cell lymphoma has grown as a result of rising R&D spending and an increase in lymphoma cases. The medication treats peripheral t-cell lymphoma, a rare subtype of t-cell lymphoma (pTCL). AFM13 is being studied as a monotherapy for treating CD30-positive pTCL that has relapsed or is resistant. As a result of the studies, the market is anticipated to grow favorably over the forecast period.
Asia-Pacific is anticipated to grow significantly during the forecast period. China's main market expansion drivers are the rising prevalence of t-cell lymphoma and the country's well-established healthcare system. Angio-immunoblastic t-cell lymphoma is one of the t-cell lymphomas that affect older adults most frequently. As a result, the market demand for therapeutics is anticipated to be driven by China's expanding elderly population. Additionally, the country's drug approvals are anticipated to speed up market growth over the forecast period. Additionally, businesses are putting much effort into R&D initiatives related to treating t-cell lymphoma.
The Gulf Cooperation Council (GCC) region comprises Saudi Arabia, Kuwait, Bahrain, Qatar, the United Arab Emirates, and Oman. With an increasing focus on early diagnosis and preventive care as a crucial component of society's overall well-being, countries like the United Arab Emirates and Saudi Arabia are slowly catching up regarding healthcare quality to developed markets. The major market players are also expanding in the area to increase their market share. Numerous organizations have been engaged in cancer research over the years due to the rising incidence of non-lymphoma Hodgkin's cancer in the area. To raise the standard of cancer care, the King Abdullah Medical City Oncology Center in Mecca, Saudi Arabia, engages in research and education. As a result, the market is expanding due to several factors, including the high incidence of targeted cancer, the rising geriatric population, and increased research activities.
The Brazilian market is anticipated to experience significant growth over the forecast period. The main factors driving the expansion of the regional market are the rising incidence of t-cell lymphoma cancer cases and the growing public awareness of early diagnostics. Brazil has a relatively high non-Hodgkin lymphoma burden compared to other nations in the region. According to GLOBOCAN data, 11,400 new cases of non-Hodgkin lymphoma were reported in Brazil in 2020, and 17,900 cases are anticipated by 2040. Since t-cell lymphoma causes most non-Hodgkin lymphoma cases, the rising burden of this illness also signals a rising burden for t-cell lymphoma, fueling the market's expansion.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|